Deutsche Bank sees psychedelic drug developer tripling

Deutsche Bank analysts are optimistic about a biopharmaceutical company focused on psychedelic therapies, projecting a potential stock increase of over 230%. The firm's confidence stems from two key drugs in development aimed at treating treatment-resistant depression. This positive outlook suggests a growing mainstream acceptance and investment interest in the therapeutic potential of psychedelic compounds, signaling a significant shift in the mental health treatment landscape.